Oct 28 2011
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine (known as RTS,S) actually so far represents only incremental progress -- a scientific achievement which may still turn out to have little practical utility in the real world." Paulson cites the fact that "the findings largely repeat earlier 'interim' results"; the cost of the vaccine, which has not yet been confirmed; and difficulty developing a malaria vaccine that offers an acceptable level of protection, as reasons why the vaccine may not be successful (10/25).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |